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Stephen R. Daniels, MD, PHDSEE PAGE 1250S creening for lipid disorders in childhood andadolescence has been controversial. Althoughit is well documented that atherosclerotic car-
diovascular disease is the number 1 cause of death
in the United States and that elevated cholesterol,
particularly low-density lipoprotein cholesterol
(LDL-C), is a major risk factor for the development
of disease (1), many issues regarding screening in
children remain in question.
Various entities, such as the National Heart, Lung,
and Blood Institute; the National Cholesterol Educa-
tion Program; the American Academy of Pediatrics;
and the National Lipid Association and the American
Heart Association, have recommended some form of
screening for lipid disorders in children (2). However,
the U.S. Preventive Services Task Force has found
insufﬁcient evidence for or against cholesterol
screening in childhood (3). Clearly, there is a need for
more evidence to make the best clinical decisions.
Several approaches to screening for lipid disorders
in children have been proposed, including screening
on the basis of family history, which is sometimes
referred to as cascade screening, universal screening
of all children, or no screening at all until later in
adulthood. Even if one accepts that screening has
merit, many questions remain, such as what is the
goal of screening, what is the best age for screening,
which lipid measure is most useful, and what cut
point would be used to indicate abnormality?
In lipid screening for adults, it is generally assumed
that all measures in the lipid proﬁle, including
triglycerides, high-density lipoprotein cholesterol
(HDL-C), and LDL-C, are important. It is also generally
assumed that there is a continuous risk function so*Editorials published in the Journal of the American College of Cardiology
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of atherosclerosis. Epidemiological data in adults
allow risk factors to be combined in a way that esti-
mates the risk of an adverse cardiovascular event in
the subsequent 10 years (4). This estimate of risk is
then used to make clinical decisions.
Unfortunately, such epidemiological data in chil-
dren, which could be used to calculate a lifetime risk
of the development of cardiovascular disease for in-
dividual patients, are lacking. This means that lipid
screening in children is fundamentally different from
that in the adult population. The primary focus of lipid
screening in children should be on how to identify
young individuals with genetic causes of dyslipide-
mia, such as familial hypercholesterolemia (FH). FH
results in LDL-C, which is elevated substantially above
the 95th percentile for age and is a clearly elevated
lifetime risk of cardiovascular disease (5). However,
even if one accepts genetic dyslipidemia as the target
for screening, a number of questions remain regarding
the best approach to accomplishing this in practice.In this issue of the Journal, the study byKlancar et al.
(6) provides some useful information. They took
advantage of a universal lipid screening process in
children that was adopted in Slovenia, which has a
population ofw2million citizens. The country adopted
a universal lipid screening program in children 5 years
of age in 1995. By 2013, this screening program was
reaching 20,000 children at 5 years of age. Evaluation
of this experience is important as there are few studies
of universal pediatric lipid screening in practice.
For children born between 1989 and 2009, they
identiﬁed 272 children with either total cholesterol
>231.7 mg/dl or total cholesterol >193.1 mg/dl and a
positive family history of premature cardiovascular
disease. These individuals were then genotyped for
variants in the LDL receptor, apolipoprotein (apo) B,
apo E, and proprotein convertase subtilisin/kexin
type 9 (PCSK9) to evaluate whether they had known
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1259disease-causing mutations. Of 272 individuals identi-
ﬁed, 155 (57%) had disease-causing mutations: 38.6%
in the LDL receptor and 18.4% in apo B, with
none in PCSK9. In the individuals without disease-
causing mutations, 51 (18.7%) were carriers of a
hypercholesterolemia-associated apo E E4 isoform.
No known genetic abnormality was identiﬁed in the
remaining 66 individuals (24.3%).
These screening results from Slovenia are most
consistent, with a prevalence of heterozygous FH of
1 in 500 individuals. Studies from other countries
have estimated the prevalence to range from 1 in 200
to 1 in 500 (7). This is a range for prevalence that in-
dicates that heterozygous FH is a relatively common
genetic abnormality and the most common mono-
genetic disorder leading to coronary heart disease.
This high prevalence and low rate of early clinical
detection would support a screening strategy to
identify affected individuals.
The question of family history as a potential iden-
tiﬁer of high-risk children is important. Klancar et al.
report that a negative family history was found in
one-half to three-fourths of patients with a disease-
causing or disease-associated genetic variant. This
supports the concept that the family history is not a
reliable indicator of pediatric patients with FH. This
result would also tend to support the universal
approach to screening for individuals with FH as
opposed to cascade screening.
There were some limitations to the data collected
by Klancar et al. (6). For example, the percentage of
children not screened for dyslipidemia at 5 years of
age, or later if they were missed at age 5, is unknown.
It does appear that awareness of this screening
approach increased with time as the number of chil-
dren screened increased over time. Only total
cholesterol was measured in the universal screening
program. Thus, it is not possible to compare the per-
formance of different lipid measures at the initial
screening. Patients referred from the primary care
physician to a tertiary clinic did have more complete
lipid testing. However, it is also not possible to know
how many with an elevated total cholesterol at
screening were not referred or refused the visit to a
tertiary clinic and would not have had further testing.
Finally, family history was collected via question-
naire but was not veriﬁed via medical records. Thus,there could have been substantial misclassiﬁcation of
family history, but the extent of that is not known.
Although the work of Klancar et al. (6) is helpful in
elucidating some aspects of universal screening, there
are many practical aspects of this approach to
screening in childhood for FH that remain unclear.
Some of the important unanswered issues include the
age of 5 years chosen for screening in Slovenia. The
optimal age for screening remains unknown. It is of
interest that even though screening was done at
5 years of age, the mean age at referral to an appro-
priate clinic for further evaluation and treatment
was 7.3 years. The current recommended age for
screening in the United States is between 9 and 11 years
of age (2). This was designed to avoid the decrease in
LDL-C, which occurs during puberty. However, it is not
clear how quickly individuals who are screened in the
United States and have a positive result are then seen
for further evaluation and treatment.
The experience with lipid screening in Slovenia
raises some other important practical questions. It
took more than a decade and a half to fully implement
the universal screening program. It would be useful
to know more about the barriers to full implementa-
tion. Although it is helpful to know the prevalence of
those with known disease-causing mutations using
the screening approach used in Slovenia, questions
remain regarding the optimal lipid measure to use in
screening (total cholesterol, LDL-C, or non–HDL-C)
and what cut point to use. It also is not clear whether
lipid values alone or a combination of lipid values and
family history would perform best in identifying
children with FH. The role of genetic testing in clin-
ical practice also remains unclear.
More evidence is required to determine the
optimal approach to screening for children with FH.
Experience with screening programs such as the
one in Slovenia is useful, but well-designed pro-
spective studies to evaluate the screening process
will be even more important to provide the needed
answers.
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